Boston, MA 06/17/2014 (wallstreetpr) – Oracle Corporation (NYSE:ORCL) has agreed to pay $15 million in lawyer’s fees so as to settle a shareholder case which alleged the company of buying a company leveraged by founder Larry Ellison.
Case History
The biggest manufacturer of database software had acquired Pillar Data Systems, Inc. in June 2011, a San Jose, California based data storage systems providing company. The deal, as investors alleged, was meant to benefit only Ellison, who enjoyed 55% ownership of the company.
In October, Ellison consented with forgoing a potential $575 million payout that the sale would had brought in, in order to settle shareholders’ claim. The settlement was however conditional on Oracle winning a court permit demanding insurers to pay legal fees of $20 million, according to the lawsuit filed in the Delaware Chancery Court in Wilmington.
In January, a judge rejected the request, dismissing the Redwood City, California based company’s lawsuit demanding a forced payment by the London based insurer, Beazley Plc. According to the June 16 filings, the judgment was revised and Oracle now needs to pay $5 million less in attorney’s fees itself. Oracle still denies any wrongdoing in this case.
Contribution To Life Sciences Studies
Oracle Corporation (NYSE:ORCL) announced the introduction of “Oracle Health Sciences Data Management Workbench” to help Life Sciences Organization scope up with the increasingly demanding needs of data management and warehousing. Oracle efforts aims at addressing the increasing complicacies involved with managing data in these sectors. It seeks to integrate, merge and access clinical data with higher efficiency and speed. It features automated data loading, transformation and filtering processes. This will allow study sponsors to make quicker and more informed decisions so that they can contribute more effectively in improving control and supporting trials and adaptive studies. It would also accelerate clinical studies and trials while bringing out solutions within shorter span of time into the market.
